These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 17053363)

  • 21. Acid suppressive therapy and the effects on protease inhibitors.
    Fulco PP; Vora UB; Bearman GM
    Ann Pharmacother; 2006 Nov; 40(11):1974-83. PubMed ID: 17077173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavir.
    Guiard-Schmid JB; Poirier JM; Bonnard P; Meynard JL; Slama L; Lukiana T; Jaillon P; Pialoux G
    AIDS; 2005 Nov; 19(16):1937-8. PubMed ID: 16227815
    [No Abstract]   [Full Text] [Related]  

  • 23. Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 case reports.
    Gallagher DP; Kieran J; Sheehan G; Lambert J; Mahon N; Mallon PW
    Clin Infect Dis; 2008 Aug; 47(3):e36-8. PubMed ID: 18558878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.
    Rodríguez Nóvoa S; Barreiro P; Rendón A; Barrios A; Corral A; Jiménez-Nacher I; González-Lahoz J; Soriano V
    Clin Infect Dis; 2006 Jan; 42(2):291-5. PubMed ID: 16355344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir.
    Gianotti N; Guffanti M; Galli L; Margonato A; Chiaravalli G; Bigoloni A; Lazzarin A; Castagna A
    AIDS; 2007 Jul; 21(12):1648-51. PubMed ID: 17630564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
    Luber AD; Brower R; Kim D; Silverman R; Peloquin CA; Frank I
    HIV Med; 2007 Oct; 8(7):457-64. PubMed ID: 17760738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.
    Keiser PH; Nassar N
    Int J STD AIDS; 2008 Aug; 19(8):561-2. PubMed ID: 18663047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
    Cleijsen RM; van de Ende ME; Kroon FP; Lunel FV; Koopmans PP; Gras L; de Wolf F; Burger DM
    J Antimicrob Chemother; 2007 Oct; 60(4):897-900. PubMed ID: 17704117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application.
    Keil K; Hochreitter J; DiFrancesco R; Zingman BS; Reichman RC; Fischl MA; Gripshover B; Morse GD
    Ther Drug Monit; 2007 Feb; 29(1):103-9. PubMed ID: 17304157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
    Chetchotisakd P
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):801-5. PubMed ID: 19735222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.
    Gérard L; Chazallon C; Taburet AM; Girard PM; Aboulker JP; Piketty C
    Antivir Ther; 2007; 12(1):31-9. PubMed ID: 17503745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
    Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G
    Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atazanavir in plasma-exchange treatment.
    Attema-de Jonge ME; Burger DM; Franssen EJ; Brinkman K
    AIDS; 2007 Apr; 21(7):884-5. PubMed ID: 17415050
    [No Abstract]   [Full Text] [Related]  

  • 35. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
    Ruane PJ; Luber AD; Wire MB; Lou Y; Shelton MJ; Lancaster CT; Pappa KA;
    Antimicrob Agents Chemother; 2007 Feb; 51(2):560-5. PubMed ID: 17088488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy.
    Jenny-Avital ER; Joseph K
    Clin Infect Dis; 2009 May; 48(10):1471-4. PubMed ID: 19368504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects.
    Singh K; Dickinson L; Chaikan A; Back D; Fletcher C; Pozniak A; Moyle G; Nelson M; Gazzard B; Herath D; Boffito M
    Clin Pharmacol Ther; 2008 Jun; 83(6):867-72. PubMed ID: 17898705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo enhancement in bioavailability of atazanavir in the presence of proton-pump inhibitors using mesoporous materials.
    Xia X; Zhou C; Ballell L; Garcia-Bennett AE
    ChemMedChem; 2012 Jan; 7(1):43-8. PubMed ID: 22144293
    [No Abstract]   [Full Text] [Related]  

  • 39. Alopecia associated with ritonavir-boosted atazanavir therapy.
    Torres HA; Barnett BJ; Arduino RC
    AIDS; 2007 Jun; 21(10):1391-2. PubMed ID: 17545728
    [No Abstract]   [Full Text] [Related]  

  • 40. Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine.
    Manavi K; McDonald A; Al-Sharqui A
    AIDS; 2007 Mar; 21(5):643-5. PubMed ID: 17314527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.